Full Text of PDF (450k)
Article in Japanese
Abstract
Case Report
A case of drug-induced interstitial pneumonia because of teneligliptin
Junko Itano Yasushi Tanimoto Mitsunori Ishiga Fumiyo Namba Hisaaki Tanaka Ryo Soda
Department of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center
ABSTRACT
A 69-year-old woman developed a cough and was diagnosed with mild interstitial pneumonia 2 years ago, after which her case was followed up. She was referred to our hospital because her cough exacerbated approximately 40 days after oral administration of teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was started for treatment of type 2 diabetes mellitus. A chest CT showed new diffuse ground-glass opacities and patchy shadows in both lungs. Bronchoalveolar lavage fluid showed an elevated total cell count with lymphocytic predominance, and a drug lymphocyte stimulation test by teneligliptin was positive. Based on these findings, the patient was diagnosed with teneligliptin-induced lung disease (interstitial pneumonia) associated with pre-existing interstitial pneumonia. DPP-4 inhibitors may induce severe interstitial pneumonia.
KEYWORDS
Drug-induced lung disease Dipeptidyl peptidase-4 (DPP-4) inhibitor Teneligliptin
Received 16 Oct 2015 ／ Accepted 15 Feb 2016
AJRS, 5(3): 126-130, 2016
Copyright © The Japanese Respiratory Society All Rights Reserved.